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Abstract Patients with severe or difficult-to-treat asthma
account for substantial asthma morbidity, mortality, and
healthcare burden despite comprising only a small propor-
tion of the total asthma population. TENOR, a multicenter,
observational, prospective cohort study was initiated in
2001. It enrolled 4,756 adults, adolescents and children with
severe or difficult-to-treat asthma who were followed semi-
annually and annually for three years, enabling insight to be
gained into this understudied population. A broad range of
demographic, clinical, and patient self-reported assessments
were completed during the follow-up period. Here, we
present key findings from the TENOR registry in relation
to asthma control and exacerbations, including the identifi-
cation of specific subgroups found to be at particularly
high-risk. Identification of the factors and subgroups
associated with poor asthma control and increased risk
of exacerbations can help physicians design individual
asthma management, and improve asthma-related health
outcomes for these patients.
Keywords Severe asthma .Difficult-to-treat asthma .
Asthmacontrol .Exacerbation
B. E. Chipps (*)
Capital Allergy and Respiratory Disease Center,
Sacramento, 5609 J Street, Suite C,
Sacramento, CA 95819, USA
e-mail: BChipps@CapitalAllergy.com
R. S. Zeiger
Department of Allergy, Kaiser Permanente SD,
7060 Clairemont Mesa Blvd,
San Diego, CA 92111, USA
e-mail: Robert.S.Zeiger@kp.org
A. Dorenbaum:T. Haselkorn
Genentech, Inc,
MS-58B, 1 DNA Way,
South San Francisco, CA 94080, USA
A. Dorenbaum
e-mail: dorenbaum.alejandro@gene.com
T. Haselkorn
e-mail: haselkorn.tmirah@gene.com
L. Borish
Asthma and Allergic Disease Center, University of Virginia,
Charlottesville, VA 22908, USA
e-mail: lb4m@virginia.edu
S. E. Wenzel
Pulmonary, Allergy and Critical Care Medicine,
University of Pittsburgh Asthma Institute,
NW 931 Montefiore, 3459 Fifth Ave,
Pittsburgh, PA 15213, USA
e-mail: wenzelse@upmc.edu
D. P. Miller
ICON Clinical Research,
188 The Embarcadero # 200,
San Francisco, CA 94105, USA
e-mail: Dave.Miller@iconplc.com
M. L. Hayden
University of Virginia Employee Health,
P.O. Box 800398, Charlottesville, VA 22908, USA
e-mail: mlou317@verizon.net
E. R. Bleecker
Center for Genomics and Personalized Medicine Research,
Wake Forest University School of Medicine,
Medical Center Blvd,
Winston-Salem, NC 27157, USA
e-mail: ebleeck@wakehealth.edu
Curr Respir Care Rep (2012) 1:259–269
DOI 10.1007/s13665-012-0025-xIntroduction
According to World Health Organization (WHO) estimates,
235 million people worldwide currently have asthma [1].
Although patients with severe or difficult-to-treat asthma
comprise only a small proportion (<15 %) of the total
asthma population, they account for substantial asthma
morbidity, mortality, and healthcare costs [2–6]. As for all
patients with asthma, the primary objective of treatment for
patients with severe disease is to achieve and maintain
clinical control [7￿￿]. To improve outcomes among these
patients, it is necessary to understand the extent to which
this objective is being met, identify barriers that may hinder
achievement of asthma control, and ascertain whether
specific subgroups of patients are at increased risk of
poor control.
Large registries that accumulate data from “real-world”
settings are a valuable tool with which to evaluate treatment
outcome. In 2001, a multicenter, observational, prospective
cohort study, The Epidemiology and Natural History of
Asthma: Outcomes and Treatment Regimens (TENOR),
was initiated to study patients described by their physicians
as having severe or difficult-to-treat asthma [8, 9]. Data
from TENOR have been reported in more than 25 publica-
tions, and provide insight into asthma-related health out-
come and barriers to optimum asthma care for these
patients. Analyses of TENOR data have also provided the
opportunity to characterize patients with severe or difficult-
to-treat asthma with regard to atopy. For example, in
TENOR most patients were found to have high immuno-
globulin (IgE) levels, particularly males, children, smokers,
non-white racial or ethnic group, and adults with childhood-
onset disease [10]. In young patients, IgE levels were found
to be associated with asthma severity [10], and high
frequencies of comorbid allergic diseases and allergen
sensitization were seen [11].
In this review, we summarize the findings from TENOR
in relation to asthma control and asthma exacerbations in
patients with severe or difficult-to-treat disease and further
examine specific patient subgroups within this population.
Defining asthma severity and control
When TENOR was initiated in 2001, asthma severity was
defined in the National Heart Lung and Blood Institute
(NHLBI) guidelines according to symptoms, activity limi-
tation, rescue medication use, and exacerbation frequency
[12]. In 2007, these guidelines were updated, recommend-
ing that physicians assess asthma severity using two
domains: current impairment (day-to-day symptoms and
limitation of activity) and future risk (likely outcome if
patient remains on current treatment, based on asthma se-
verity, history, and probability of exacerbation) [13, 14].
Similarly, current Global Initiative for Asthma (GINA)
guidelines note that asthma severity encompasses both the
underlying nature of the diseaseandtheresponsetotreatment
[7￿￿]. Consequently, the GINA guidelines classify asthma as
severe if it requires high intensity treatment or if control is not
achieved despite such treatment. Both NHLBI and GINA
guidelines also recognize the importance of evaluating future
risk of exacerbation, on the basis of current clinical control,
lung function, and exacerbation history [7￿￿, 13].
Data from the TENOR registry have proved extremely
useful for identifying patients at high-risk of poor asthma
control and frequent asthma exacerbations. This review
summarizes the analyses and findings related to asthma
control and exacerbations in TENOR through the evolution
of these terms and definitions.
The TENOR registry
Objectives and design
The primary objective of TENOR was to collect prospective
data to improve our understanding of the natural history of
asthma in patients with severe or difficult-to-treat disease
[8]. Secondary objectives were to examine the relationship
between features of asthma treatment and outcome, to
observe the frequency of pre-defined comorbid condi-
tions, and to describe the relationship between IgE levels
and disease.
The TENOR study design has been described in detail
elsewhere [8] and is shown in Fig. 1. TENOR is a large,
observational study of severe or difficult-to-treat asthma
which enrolled 4,756 patients (3,489 adults ≥18 years, 497
adolescents 13–17 years, and 770 children 6–12 years) with
diverse racial and ethnic backgrounds, and from different
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Patients were included in the TENOR registry if they had
severe or difficult-to-treat asthma, with asthma severity
being determined by their physician. Patients with mild or
moderate asthma were therefore eligible for enrollment if
their asthma was considered difficult-to-treat. Patients were
assessed as having “difficult-to-treat” asthma on the basis of
pre-specified criteria, including the need for multiple drugs,
occurrence of frequent exacerbations, severe exacerbations,
inability to avoid asthma triggers, and use of a complex
treatment regimen [8]. Patients were also required to have
high use of the healthcare system (≥2 unscheduled care
visits for asthma or ≥2 oral corticosteroid (OCS) courses)
or high medication use (requiring ≥3 medications to control
asthma or requiring long-term daily high-doses of inhaled
corticosteroids (ICS)) in the previous 12 months. At enroll-
ment, 48 % of patients had severe asthma, 48 % moderate
asthma, 3 % mild asthma, and 96 % difficult-to-treat asthma.
After enrollment, patients completed seven study visits over
three years, during which a range of demographic, clinical,
standard laboratory, and patient self-reported assessments
was completed.Baselinedemographicsandclinicalcharacter-
istics of the TENOR population are presented in Table 1.
At baseline, at least one asthma hospitalization or emer-
gency department (ED) visit in the previous three months
occurred in 5 % and 15 % of adults, 10 % and 17 % of
adolescents, and 9 % and 22 % of children, respectively.
Almost half of adults and children, and ~40 % of adoles-
cents reported OCS courses and unscheduled visits for
asthma in the previous three months [8]. Across all age
groups, approximately 10 % of patients reported a history
of intubation for asthma. This high healthcare utilization
was observed despite the use of multiple long-term control-
ler medications [8, 9]. Notably, of those using at least three
long-term controllers, 15 % of adults, 19 % of adolescents,
and approximately 25 % of children had visited an ED in the
three months before baseline [15￿].
Recent and future asthma exacerbation
Given the high rates of healthcare utilization in the TENOR
cohort, subsequent analysis has focused on identifying spe-
cific predictors for future asthma exacerbations. In adults,
adolescents, and children, after assessing a broad range of
variables, recent asthma exacerbation was the strongest pre-
dictor of future asthma exacerbation [16]. In patients aged
≥12 years, those who reported an asthma-related ED visit or
overnight hospitalization in the three months before baseline
were more than sixfold more likely (odds ratio (OR)06.33;
95 % confidence interval (CI) 4.57, 8.76), to experience a
future severe asthma exacerbation (defined as an asthma-
related ED visit, overnight hospitalization, or an asthma-
related death) at the 18-month follow-up (Fig. 2)[ 16]. After
adjusting for demographic and clinical factors, the risk of
future severe exacerbation remained high (OR03.77; 95 %
CI 2.62, 5.43). When analysis was individually adjusted for
various asthma severity measures, the increased risk was
Fig. 1 TENOR study design [15￿]. Adapted from Chipps et al. 2012
[15￿]; copyright (2012), with permission from Elsevier. Asterisk, daily
high doses of inhaled steroids were defined by the American Thoracic
Society refractory asthma guidelines for adults [37] and by the 1997
National Heart Lung and Blood Institute (NHLBI) guidelines for
children [12]
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5.62; 95 % CI 4.03, 7.83; National Asthma Education and
Prevention Program guideline assessed: OR05.07; 95 % CI
3.62, 7.11; GINA guideline assessed: OR05.32; 95 % CI
3.80, 7.47). When adjusted for asthma control (using the
asthma therapy assessment questionnaire; ATAQ), the risk of
future severe exacerbation was nearly fourfold (OR03.90;
95 % CI 2.77, 5.50). An increased risk of future exacerbation
requiring an OCS course was also seen if patients had a recent
exacerbation requiring an OCS course in the three months
before baseline (Fig. 2)[ 16].
Similarly, separate analysis for children (aged 6–11 years)
assessed the occurrence and association of a recent severe
exacerbation defined as one or more OCS courses during the
three months before each of three annual visits (baseline,
Month 12, and Month 24), and a future severe exacerbation,
defined as one or more OCS courses six or twelve months
later. A future severe exacerbation at six months was most
strongly predicted by a recent severe exacerbation (OR0
3.08; 95 % CI 2.21, 4.28) and having 3 or 4 allergic
triggers (OR02.05; 95 % CI 1.31, 3.20) [17￿] (Table 2,
Model II). Other predictors of a future severe exacerbation
at six months included non-white race (OR01.77; 95 %
CI 1.25, 2.51) and very poorly controlled asthma, as
defined by the NHLBI guidelines (OR01.59; 95 % CI
1.14, 2.23).
Table 1 TENOR baseline demographics and clinical characteristics [8]
Variable Overall Adults
(≥18 years)
Adolescents
(13–17 years)
Children
(6–12 years)
Patients, n (%) 4756 (100) 3489 (73.36) 497 (10.45) 770 (16.19)
Age, mean ± SD, years 38.9±20.92 48.9±14.85 14.5±1.34 9.5±1.88
Weight, mean ± SD,kg 75.2±26.53 83.9±2.22 66.9±21.03 41.1±16.64
BMI, mean ± SD,kg/m
2 28.3±8.59 30.4±7.73 25.4±9.86 20.7±6.17
IgE, geometric mean, IU/mL 106.6 85.2 223.8 182.5
Sex, n (%)
Female 2945 (62.2) 2475 (71.2) 213 (42.9) 257 (33.5)
Male 1792 (37.8) 999 (28.8) 283 (57.1) 510 (66.5)
Race or ethnicity, n (%)
White 3555 (75.1) 2769 (79.8) 323 (65.4) 463 (60.4)
Black 712 (15.0) 404 (11.6) 115 (23.2) 193 (25.2)
Hispanic 303 (6.4) 197 (5.7) 36 (7.3) 70 (9.1)
Asian or Pacific Islander 72 (1.5) 57 (1.6) 7 (1.4) 8 (1.0)
Other 91 (1.9) 44 (1.2) 14 (2.8) 33 (4.3)
Physician assessment of severity, n (%)
Mild 149 (3.2) 91 (2.6) 19 (3.8) 39 (5.1)
Moderate 2285 (48.4) 1585 (46.1) 237 (47.9) 453 (59.1)
Severe 2285 (48.4) 1771 (51.2) 239 (48.3) 275 (35.9)
Smoking history, n (%)
Never smoked 3454 (73.1) 2207 (63.7) 483 (97.8) 764 (99.6)
Past smoker 1113 (23.6) 1110 (32.0) 3 (0.6) 0
Current smoker 159 (3.4) 148 (4.3) 8 (1.6) 3 (0.4)
Predicted pre-bronchodilator FEV1, n (%)
≤60 % 1015 (23.5) 893 (27.8) 69 (15.7) 53 (8.0)
>60 % to <80 % 1292 (29.9) 1015 (31.6) 104 (23.7) 173 (26.0)
≥80 % 2007 (46.5) 1302 (40.6) 266 (60.6) 439 (66.0)
Pre-bronchodilator FEV1, (% predicted), mean ± SD 77.2±23.28 74.2±23.45 84.0±21.63 87.0±19.57
Post-bronchodilator FEV1 (% predicted), mean ± SD 82.5±23.04 79.0±23.08 91.1±21.03 93.9±18.50
QoL score
a, mean NA 4.6 5.2 5.4
Adapted from Dolan et al. 2004 [8]; copyright (2004), with permission from Elsevier
aAsthma-related QoL measured using the Juniper Mini Asthma Quality of Life Questionnaire for patients ≥13 years and the Pediatric Asthma
Quality of Life Questionnaire with Standardized Activities for patients aged 6–12 years
BMI, body mass index; FEV1, forced expiratory volume in 1 second; IgE, immunoglobulin E; NA, not applicable; QoL, quality of life; SD,
standard deviation; TENOR, the epidemiology and natural history of asthma: outcomes and treatment regimens
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that a recent severe exacerbation (within the previous three
months) is an important independent predictor of a future
severe exacerbations in severe or difficult-to-treat asthma.
Asthma control and asthma exacerbations
We also examined the relationship between asthma control
and asthma exacerbations. The findings consistently
revealed that poor asthma control, whether defined by the
patient (using self-reported, validated instruments) or by
national asthma guideline classifications, was strongly asso-
ciated with an increased risk of asthma exacerbations. In an
early analysis, TENOR used the ATAQ in patients ≥18 years
to assess the association between baseline asthma control,
and subsequent severe asthma-related healthcare events
within the first year of follow-up. After adjustment for
covariates, patients with poor asthma control at baseline
(three or four control problems) were found to be at in-
creased risk of: unscheduled office visits (relative risk
(RR)02.8; 95 % CI 2.4, 3.2), requiring a course of OCS
(RR02.9; 95 % CI 2.5, 3.3), ED visits (RR04.1; 95 % CI
2.7, 6.2), and hospitalization (RR013.6; 95 % CI 7.4, 24.9)
within the first year of follow-up, compared with patients
with no asthma control problems [18] (Fig. 3).
After the 2007 update to the NHLBI asthma guidelines
[13], we evaluated the classification scheme for asthma
control based on the impairment domain of the guidelines
for identifying patients at risk of future asthma exacerbation
[19￿]. Using data representing all components of the impair-
ment domain at baseline, Month 12, and Month 24, patients
were categorized into two groups: those whose asthma was
consistently very poorly controlled from baseline through
two years of follow-up, and those whose asthma improved
from very poorly controlled at baseline with improvement
maintained throughout two years of follow-up. In multivar-
iate analysis, pediatric patients whose asthma was consis-
tently very poorly controlled were at sixfold increased risk
of hospitalization, ED visit, or OCS burst (OR06.4; 95 %
CI 1.2, 34.5) at the Month 30 visit, compared with those
who improved over the two-year period. Adult and adoles-
cent patients who were consistently very poorly controlled
Fig. 2 A) Odds of future
exacerbations associated with
recent exacerbations, B) Odds
of future steroid burst
associated with recent steroid
bursts, adjusted for
demographics, asthma severity,
and asthma control [16].
Adapted from Miller et al. 2007
[16]; copyright (2007), with
permission from Elsevier. Re-
cent referred to the three
months before baseline. Severe
exacerbations was defined as
either an asthma-related
emergency department visit or
hospitalization. X axis is on a
logarithmic scale. ATAQ,
asthma therapy assessment
questionnaire; GINA, global
initiative for asthma; NAEPP,
national asthma education and
prevention program
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CI 1.7, 4.8), or have a hospitalization, ED visit, or OCS
course when these outcomes were assessed as a composite
measure (OR03.2; 95 % CI 1.9, 5.3; Fig. 4). These data
from TENOR provided validation for the impairment do-
main of the 2007 NHLBI guidelines as an effective tool for
classifying and managing patients with severe or difficult-
to-treat asthma.
Table 2 Predictors of future exacerbations in children aged 6–11 years [17￿]
Predictor
a Model I
b Model II
c
Stepwise model where future exacerbation includes
6-month and 12-month time frames
Additional stepwise reduction of model including
only 6-month events
OR 95 % CI p value OR 95 % CI p value
Recent exacerbation 1.99 1.51, 2.61 <0.001 3.08 2.21, 4.28 <0.001
Non-white vs. white 1.76 1.34, 2.32 <0.001 1.77 1.25, 2.51 0.001
Allergic triggers
d
1 or 2 allergic triggers 1.39 0.99, 1.95 0.059 1.26 0.82,1.93 0.29
3 or 4 allergic triggers 2.01 1.40, 2.89 <0.001 2.05 1.31, 3.20 0.002
NHLBI guidelines control impairment domain
e
VPC vs. NWC 1.40 1.08, 1.80 0.010 1.59 1.14, 2.23 0.007
WC vs. NWC 0.89 0.45, 1.75 0.73 0.85 0.37, 1.92 0.69
Duration of asthma (per year) 1.06 1.01, 1.12 0.021 –– –
Non-allergic triggers
f,1 –2 vs. 0 1.52 1.07, 2.16 0.019 –– –
Adapted from Haselkorn et al. 2009c [17￿]; copyright (2009), with permission from Elsevier
aThe stepwise model candidate predictors were age, duration of asthma, sex, white/non-white, obesity, number of long-term controllers, allergic
triggers, non-allergic triggers, passive smoking, NHLBI 2007 asthma control (impairment domain), and median income in zip code. Variables that
are components of the NHLBI guidelines impairment domain (e.g. ATAQ control problems, spirometry and symptoms) were included only as
components of the NHLBI definition
bThe event of interest (future severe exacerbation) was observed in 469 assessments of 255 patients
c The event of interest (future severe exacerbation) was observed in 250 assessments of 186 patients
dPatients with no triggers are the reference group. Allergic triggers include pollen, moldy/musty places, animals, and dust and are based on the
question, “Symptoms of asthma are a result of …”
eAs NWC and WC are not meaningfully different, a single OR was computed for VPC vs. all others, and was used to calculate the predicted
probabilities (OR 1.62; 95 % CI 1.16, 2.25, p00.004)
fNon-allergic triggers include emotional stress and cold/sinus infection.
ATAQ, Asthma Therapy Assessment Questionnaire; CI, confidence interval; NHLBI, National Heart, Lung and Blood Institute; NWC, not well
controlled; OR, odds ratio; VPC, very poorly controlled; WC, well controlled
Fig. 3 Adjusted risk of acute
asthma-related healthcare
events by baseline level
of asthma control [18].
Adapted from Sullivan et al.
2007 [18]. Asthma control
was determined at baseline
by use of The Asthma Therapy
Assessment Questionnaire. ED,
emergency department
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by assessing the affect of individual components of the
impairment domain on the classification of asthma con-
trol and prediction of asthma exacerbations. It was found
that omission of individual components of the impair-
ment domain resulted in asthma control being wrongly
classified in 11–39 % of patients [20￿]. The strongest
predictor of an asthma exacerbation at 12 months was a
previous exacerbation at baseline (in adults and adoles-
cents: OR02.93; 95 % CI 2.38, 3.61 and in children:
OR02.94; 95 % CI 1.71, 5.07). In addition, very poorly
controlled asthma, classified on the basis of use of short-
acting β2-agonists (SABAs), was associated with a two-
fold higher exacerbation risk in children (OR02.03;
95 % CI 1.17, 3.52). In adults and adolescents, signifi-
cant predictors of exacerbations at Month 12 were very
poorly controlled asthma on the basis of lung function
(OR01.66; 95 % CI 1.34, 2.06) and very poorly con-
trolled asthma on the basis of the ATAQ control score
(OR01.94; 95 % CI 1.56, 2.40). In addition, for adults
and adolescents, very poorly controlled asthma and not
well controlled asthma, classified on the basis of the use
of SABAs, was also associated with increased exacerba-
tion risk (OR01.49; 95 % CI 1.19, 1.85). This study
reaffirmed that a recent asthma exacerbation is the stron-
gest predictor of a future exacerbation and that, although
specific components of the NHLBI impairment domain
may be more important than others in predicting asthma
exacerbations, the combined use of the components is
essential for improving the identification of patients at
high-risk of future exacerbations [20￿].
Asthma control and asthma exacerbations in high-risk
patient subgroups
The TENOR registry has provided a valuable opportunity to
evaluate asthma control and exacerbations in several patient
subgroups, including older patients (≥65 years) who are
often excluded from clinical trials. Characterization of these
subgroups can assist physicians in addressing individual
disease-management needs, and may help to improve
asthma-related health outcome.
Compared with younger patients (18–64 years) in
TENOR, lower healthcare resource utilization, better
asthma-related quality of life (QoL), and fewer asthma con-
trol problems were observed for older patients, despite their
poorer lung function [21]. These findings may be related to
more intensive treatment (as evidenced by greater use of
ICS and OCS) and higher medication adherence among
older TENOR patients. Also, although older patients reported
fewer problems controlling their asthma (p<0.001), they
reported worse communication with their physicians (p00.02)
than younger patients.
Body mass index (BMI) and weight have both been
positively correlated with asthma incidence and severity,
and negatively associated with response to ICS [22–24].
For adult TENOR patients (aged ≥18 years), body weight
changes were found to affect asthma control and exacerbation
Fig. 4 Risk of asthma exacerbations at the Month 30 visit associated
with consistently very poorly controlled asthma, as defined by impair-
ment domain of the NHLBI guidelines [19￿]. Adapted from Haselkorn et
al. 2009 [19￿]; copyright (2009), with permission from Elsevier. Final
adjusted models for hospitalization and ED visits include previous
hospitalization or ED visits, number of long-term controllers, body mass
index, allergic triggers, non-allergic triggers, percent predicted FVC, race
or ethnicity, and age. Final adjusted models for corticosteroid courses
include previous corticosteroid course, chronic obstructive pulmonary
disease, non-allergic triggers, percent predicted FEV1/FVC ratio, race or
ethnicity, and age. CI, confidence interval; ED, emergency department;
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity;
NHLBI, National Heart Lung and Blood Institute
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month interval reported poorer asthma control (adjusted
OR01.22; 95 % CI 1.01, 1.49), worse QoL, and a greater
number of OCS courses (OR01.31; 95 % CI 1.04, 1.66),
than patients who maintained or lost weight.
Studies have shown that African–Americans with asthma
are more likely to experience treatment failure than white
patients, despite having fewer asthma symptoms and using
less rescue medication [26]. It has also been shown that
African–Americans tend to have more severe acute asthma
episodes than white patients, and have greater utilization of
emergency healthcare [26–28]. The underlying reasons for
increased asthma morbidity among black patients compared
with those from other racial/ethnic groups, have not been
fully elucidated. To improve understanding, a TENOR
analysis of adult patients (≥18 years) compared 243 black
patients with 1,885 white patients. One year after enrollment,
black patients were more likely to have a higher frequency
of ED visits, more problems with asthma control, poorer
QoL, and greater requirement for three or more long-term
controllers (among those with physician-assessed severe
asthma) [29]. These racial differences were not explained
by adjustment for broad sets of confounding variables,
including socioeconomics, disease severity, BMI, sensiti-
zation to allergens, medication adherence, or treatment
setting. Asthma-related behavioral and knowledge fac-
tors, which are understudied aspects of current racial
disparity research, did not differ between black and white
patients. These findings suggest the need to evaluate
genetic and pharmacogenetic factors to help explain
these racial differences.
Although treatment reverses airway obstruction in
patients with asthma, it has been noted that some patients
have persistent airflow limitation (PAFL) which is charac-
terized by a lack of reversal of obstruction, despite treat-
ment, and is associated with a high risk of morbidity and
mortality [13, 30–32]. A 2007 analysis from the TENOR
registry showed that PAFL was highly prevalent in adult
(≥18 years) patients with severe or difficult-to-treat asthma,
and can be associated with identifiable clinical and
demographic characteristics [33]. Of the 1,017 TENOR
patients included in this analysis, evidence of PAFL
Table 3 Summary table of important findings from TENOR and applications to patient care
Important findings from the TENOR cohort: Asthma control and exacerbations in patients with severe or difficult-to-treat
asthma
Ref.
Patients with severe or difficult-to-treat asthma have poor asthma control and high rates of asthma-related healthcare utilization,
despite use of multiple long-term controller medications
[8, 15￿]
Poor asthma control, whether defined by self-reported validated instruments, for example the ATAQ, or by use of NHLBI 2007
guideline classifications, is strongly associated with an increased risk of future asthma exacerbations
[18, 19￿]
Patients are at significant risk of a future asthma exacerbations if they have had a recent exacerbations in the preceding 3 months [16, 17￿]
Asthma control and exacerbations in high-risk patient subgroups with severe or difficult-to-treat asthma
Adult (≥18 years) patients who gain weight (≥5 lb during a 12-month period) are more likely to have poorer asthma control,
worse QoL, and a greater number of OCS courses compared with patients who maintain or lose weight
[25]
Adult (≥18 years) black patients are at an increased risk of asthma exacerbations, poorer asthma control, and compromised
responsiveness to some medications
[29]
PAFL is highly prevalent among adult (≥18 years) patients, particularly those of older age, male sex, black race, who are current
or past smokers, aspirin sensitive, or have a long asthma duration
[33]
Adult (≥18 years) patients with aspirin sensitivity are more likely to have severe asthma and possible remodeling of the upper
and lower airways
[36]
Applications to patient care
Recent exacerbations history (preceding 3 months) and an evaluation of the level of asthma control should be included as a
component of asthma assessment and management
[16, 17￿, 20￿]
Future exacerbations for individual patients can be predicted by use of asthma control, defined by the impairment domain of the
NHLBI 2007 asthma guidelines
[19￿]
Validated, self-assessed measures of asthma control, for example the ATAQ, are effective tools for identifying and managing
patients at greatest risk of future health impairment and severe asthma-related incidents
[18]
Physicians should be aware of the importance of good communication with patients, particularly old patients, and ensure
appropriate use of ICS and patient adherence to prescribed regimens
[21]
Strategies to prevent weight gain may help patients achieve better asthma control and improve asthma-related QoL [25]
Increased awareness of patient subgroups that are particularly at risk of poor asthma control and future exacerbations can help in
the design of asthma-management strategies for individual patients. These include patients with weight gain, black patients,
patients with PAFL, and patients with aspirin-sensitive asthma
[25, 29, 33, 36]
Adapted from Chipps et al. 2012 [15￿]; copyright (2012), with permission from Elsevier
ATAQ, Asthma Therapy Assessment Questionnaire; NHLBI, National Heart, Lung and Blood Institute; OCS, oral corticosteroids; PAFL, persistent
airflow limitation; QoL, quality of life; TENOR, The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens
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in 1 second/forced vital capacity (FEV1/FVC) ratio
≤70 % at two annual consecutive visits) was observed
for 612 (60 %). Patients with chronic obstructive pulmo-
nary disease (COPD), obesity with a restrictive respira-
tory pattern, or a ≥30 pack-year history of smoking were
excluded. Risk factors for PAFL were old age (OR per
10 years01.4; 95 % CI 1.3, 1.6), male gender (OR04.5;
95 % CI 2.3, 8.5), black ethnicity (OR02.2; 95 % CI
1.3, 2.8), current or past smoking (OR03.9; 95 % CI
1.8, 8.6 and 1.6; 95 % CI, 1.2, 2.3, respectively), aspirin
sensitivity (OR01.5; 95 % CI 1.0, 2.4), and longer
asthma duration (OR per 10 years01.6; 95 % CI 1.4,
1.8). Factors that appeared to protect against PAFL were
Hispanic ethnicity, being better educated, having a histo-
ry of atopic dermatitis, having pet(s) in the home, and
dust sensitivity. Importantly, however, no evidence of
PAFL was found for 40 % of patients analyzed, suggest-
ing PAFL may be a distinct asthma phenotype which
does not develop in all severe or difficult-to-treat patients
with asthma.
It has been noted that patients with aspirin-exacerbated
respiratory disease (AERD), which is characterized by aspi-
rin sensitivity, severe persistent asthma, extensive chronic
hyperplastic eosinophilic sinusitis, and nasal polyp forma-
tion, are at particularly high risk of asthma exacerbations
[34, 35]. Aspirin sensitivity as a risk factor for the develop-
ment of irreversible airway obstruction was evaluated for
adult patients (aged ≥18 years) in the TENOR registry [36].
Compared with patients with non-aspirin-sensitive asthma,
patients with AERD had significantly lower mean
post-bronchodilator percent predicted FEV1 (75.3 % vs.
79.9 %), were more likely to have physician-assessed severe
asthma (66 % vs. 49 %), to have been intubated for asthma
(20 % vs. 11 %), to require OCS courses (56 % vs. 46 %), or
require higher doses of ICS (34 % vs. 25 %). These findings
suggest that aspirin sensitivity is associated with increased
asthma severity, and possible remodeling of the upper and
lower airways [36].
Conclusions
Since its initiation in 2001, the TENOR registry has provided
clinicians with unique and important information that can be
used to help guide effective management of patients with
severe asthma by improved understanding of factors associ-
ated with poor asthma control and high levels of healthcare
resource use. Analysis of data from the TENOR cohort have
revealed that patients with severe or difficult-to-treat asthma
should be assessed to determine their recent exacerbation
history (previous 3 months). In addition, analyses of
data from the TENOR cohort provide strong support for
assessment of current asthma control to estimate future
exacerbation risk and guide management decisions [19￿,
20￿]. The most recent NHLBI and GINA guidelines for
the management of asthma [7￿￿, 13] both recognize the
importance of evaluating future risk of exacerbations on
the basis of assessment of exacerbations history and current
asthma control.
The TENOR registry has facilitated the identification of
several subgroups of patients with severe or difficult-to-treat
asthma who are at particular high-risk of poor asthma con-
trol and impairment. These include adult (≥18 years)
patients who gain weight (≥5 lbs over a 12-month period),
black patients, patients with PAFL, and patients with
aspirin-sensitive asthma. Increased awareness of these sub-
groups may help clinicians apply more targeted asthma
management strategies to improve asthma-related health
outcome for these patients. A summary of the important
findings from TENOR discussed in this review, and their
clinical implications, are listed in Table 3.H o w e v e r ,i t
should be noted that the findings from TENOR are repre-
sentative of specialist care in the USA, and therefore might
not be generalizable to asthmatic patients in the general
population or under primary care management.
Acknowledgments We gratefully acknowledge all participants in the
TENOR Study Group, including the dedicated investigators and study
coordinators who enrolled and collected the extensive data, ultimately
enabling all research projects to be possible, and the invaluable
collaborators and contributors to the research projects summarized in
this article (in alphabetical order): H. Barron, MD; P. D. Blanc, MD,
MSPH; B.W. Bresnahan, PhD; J. D. Campbell, PhD; H. Chen, MD,
MPH; Y. Deniz, MD; C. M. Dolan, PhD; A. Dorenbaum, MD; J. E.
Fish, MD; K. E. Fraher, MS; L. C. Grammer, MD; E. Israel, MD; C. A.
Johnson, MD; T.V. Kamath, PhD; J. H. Lee, MD; X. Li, PhD; K.
Mascia, PhD; D. A. Meyers, PhD; M. K. Miller, MS; D. R. Mink, MS;
D. J. Pasta, MS; A. T. Peters, MD; M. Pritchard, MS; L. Rasouliyan,
M S ;R .G .S l a v i n ,M D ;S .D .S u l l i v a n ,P h D ;E .H .W a r r e n ,
MBA; D. A. Wong, MD, and B. Zheng, PhD.
Editorial support was provided by professional medical writers
Lisa Quinn (CircleScience) and Paul Hutchin PhD (contracted to
CircleScience), funded by Genentech Inc.
Declaration of source of funding Genentech, Inc, South San
Francisco, CA, USA, and Novartis Pharmaceuticals, East Hanover,
NJ, USA, provided support for the preparation of this manuscript.
Disclosure B.E. Chipps: consultant arrangements with Genentech
and Novartis, is on the speakers’ bureau for Genentech and Novartis,
and has received grants for clinical research and education activity
from Genentech and Novartis; R.S. Zeiger: consultant arrangements
with Genentech and Novartis, and has received research support from
Genentech; L. Borish: consultant arrangements with Genentech and
has received research support from Genentech; D.P. Miller: employer
has Genentech as a client; M.L. Hayden: speakers’ bureau for
Genentech and Novartis; E.R. Bleecker: consultant arrangements with
Genentech and has received research support from Genentech; S.
Szefler: consultant arrangements with Genentech and Novartis; T.
Haselkorn: paid consultant of Genentech, Inc.; A. Dorenbaum: an
employee of Genentech, Inc. and holds Roche stock options; S.E.
Wenzel, E.R. Simons, and S.T. Weiss: no relevant conflicts of interest.
Curr Respir Care Rep (2012) 1:259–269 267Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
Papers of particular interest, published recently, have been
highlighted as:
￿ Of importance
￿￿ Of major importance
1. World Health Organization(WHO). Asthma fact sheet no. 207. 2011
2. Taylor WR, Newacheck PW. Impact of childhood asthma on
health. Pediatrics. 1992;90:657–62.
3. Tough SC, Hessel PA, Ruff M, Green FH, Mitchell I, Butt JC.
Features that distinguish those who die from asthma from commu-
nity controls with asthma. J Asthma. 1998;35:657–65.
4. Vollmer WM, Markson LE, O’Connor E,FrazierEA,BergerM, Buist
AS. Association of asthma control with health care utilization: a
prospective evaluation. Am J Respir Crit Care Med. 2002;165:195–9.
5. Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps BE.
Extent, patterns, and burden of uncontrolled disease in severe or
difficult-to-treat asthma. Allergy. 2007;62:126–33.
6. Szefler SJ, Zeiger RS, Haselkorn T, et al. Economic burden of
impairment in children with severe or difficult-to-treat asthma.
Ann Allergy Asthma Immunol. 2011;107:110–9.
7. ￿￿ Global Initiative for Asthma (GINA). The global strategy for
asthma management and prevention. 2011. Available at: http://
www.ginasthma.org (accessed 31 July 2012). Major global
guidelines for the management of asthma.
8. Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline
characteristics of the epidemiology and natural history of asthma:
Outcomes and Treatment Regimens (TENOR) study: a large
cohort of patients with severe or difficult-to-treat asthma. Ann
Allergy Asthma Immunol. 2004;92:32–9.
9. Chipps BE, Szefler SJ, Simons FE, et al. Demographic and clinical
characteristics of children and adolescents with severe or difficult-
to-treat asthma. J Allergy Clin Immunol. 2007;119:1156–63.
10. Borish L, Chipps B, Deniz Y, Gujrathi S, Zheng B, Dolan CM. Total
serum IgE levels in a large cohort of patients with severe or difficult-
to-treat asthma. Ann Allergy Asthma Immunol. 2005;95:247–53.
11. Haselkorn T, Szefler SJ, Simons FE, Zeiger, et al. Allergy, total
serum immunoglobulin E, and airflow in children and adolescents
in TENOR. Pediatr Allergy Immunol. 2010;21:1157–65.
12. National Heart Lung and Blood Institute, National Institutes of
Health. Expert panel report 2: guidelines for the diagnosis and
management of asthma. Washington DC: U.S. Department of Health
and Human Services. 1997. Available at: http://www.nhlbi.nih.gov/
guidelines/archive.htm (accessed 31 July 2012)
13. National Heart Lung and Blood Institute, National Institutes of
Health. Expert panel report 3: guidelines for the diagnosis and
management of asthma. Washington DC: U.S. Department of Health
and Human Services. 2007. Available at: http://www.nhlbi.nih.gov/
guidelines/asthma/asthgdln.htm (accessed 31 July 2012)
14. Pollart SM, Elward KS. Overview of changes to asthma guidelines:
diagnosis and screening. Am Fam Physician. 2009;79:761–7.
15. ￿ Chipps BE, Zeiger RS, Borish L, et al. Key findings and clinical
implications from The Epidemiology and Natural History of
Asthma: Outcomes and Treatment Regimens (TENOR) study. J
Allergy Clin Immunol. 2012. [Epub ahead of print]. A review
article focusing on the most important lessons learnt from the
TENOR study relating to burden of illness, quality of life, asthma
control and exacerbation, IgE and allergen sensitization, special
populations within TENOR, clinical tools, and genetic studies.
16. Miller MK, Lee JH, Miller DP, Wenzel SE. Recent asthma
exacerbations: a key predictor of future exacerbations. Respir
Med. 2007;101:481–9.
17. ￿ Haselkorn T, Zeiger RS, Chipps BE, et al. Recent asthma exac-
erbations predict future exacerbations in children with severe or
difficult-to-treat asthma. J Allergy Clin Immunol. 2009;124:921–7.
This study showed that recent severe asthma exacerbation is an
important predictor of future exacerbation in children.
18. Sullivan SD, Wenzel SE, Bresnahan BW, et al. Association of
control and risk of severe asthma-related events in severe or
difficult-to-treat asthma patients. Allergy. 2007;62:655–60.
19. ￿ Haselkorn T, Fish JE, Zeiger RS, et al. Consistently very poorly
controlled asthma, as defined by the impairment domain of the
Expert Panel Report 3 guidelines, increases risk for future severe
asthma exacerbations in The Epidemiology and Natural History of
Asthma: Outcomes and Treatment Regimens (TENOR) study. J
Allergy Clin Immunol. 2009;124:895–902. This study found that
future exacerbation in individual patients can be predicted by use
of asthma control defined by the impairment domain of the NHLBI
2007 asthma guidelines.
20. ￿ Zeiger RS, Yegin A, Simons FE, et al. Evaluation of the National
Heart, Lung, and Blood Institute guidelines impairment domain for
classifying asthma control and predicting asthma exacerbations.
Ann Allergy Asthma Immunol. 2012;108:81–7. This study was the
first to evaluate whether individual components of the impairment
domain of the 2007 NHLBI asthma guidelines could independently
predict future asthma exacerbation and whether some components
may be more important than others.
21. Slavin RG, Haselkorn T, Lee JH, Zheng B, Deniz Y, Wenzel SE.
Asthma in older adults: observations from the epidemiology and
natural history of asthma: outcomes and treatment regimens
(TENOR) study. Ann Allergy Asthma Immunol. 2006;96:406–14.
22. Burgess JA, Walters EH, Byrnes GB, et al. Childhood adiposity
predicts adult-onset current asthma in females: a 25-yr prospective
study. Eur Respir J. 2007;29:668–75.
23. Chinn S. Obesity and asthma: evidence for and against a causal
relation. J Asthma. 2003;40:1–16.
24. Forno E, Lescher R, Strunk R, Weiss S, Fuhlbrigge A, Celedon JC.
Decreased response to inhaled steroids in overweight and obese
asthmatic children. J Allergy Clin Immunol. 2011;127:741–9.
25. Haselkorn T, Fish JE, Chipps BE, Miller DP, Chen H, Weiss ST.
Effect of weight change on asthma-related health outcomes in
patients with severe or difficult-to-treat asthma. Respir Med.
2009;103:274–83.
26. El-Ekiaby A, Brianas L, Skowronski ME, et al. Impact of race on
the severity of acute episodes of asthma and adrenergic respon-
siveness. Am J Respir Crit Care Med. 2006;174:508–13.
27. Wechsler ME, Castro M, Lehman E, et al. Impact of race on
asthma treatment failures in the asthma clinical research network.
Am J Respir Crit Care Med. 2011;184:1247–53.
28. Erickson SE, Iribarren C, Tolstykh IV, Blanc PD, Eisner MD. Effect
of race on asthma management and outcomes in a large, integrated
managed care organization. Arch Intern Med. 2007;167:1846–52.
29. Haselkorn T, Lee JH, Mink DR, Weiss ST. Racial disparities in
asthma-related health outcomes in severe or difficult-to-treat
asthma. Ann Allergy Asthma Immunol. 2008;101:256–63.
30. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization
of the severe asthma phenotype by the National Heart, Lung, and
Blood Institute’s Severe Asthma Research Program. J Allergy Clin
Immunol. 2007;119:405–13.
31. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma
phenotypes using cluster analysis in the Severe Asthma Research
Program. Am J Respir Crit Care Med. 2010;181:315–23.
268 Curr Respir Care Rep (2012) 1:259–26932. Guerra S, Sherrill DL, Kurzius-Spencer M, et al. The course of
persistent airflow limitation in subjects with and without asthma.
Respir Med. 2008;102:1473–82.
33. Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel
SE. Risk factors associated with persistent airflow limitation in
severe or difficult-to-treat asthma: insights from the TENOR study.
Chest. 2007;132:1882–9.
34. Koga T, Oshita Y, Kamimura T, Koga H, Aizawa H. Character-
isation of patients with frequent exacerbation of asthma. Respir
Med. 2006;100:273–8.
35. Mascia K, Borish L, Patrie J, Hunt J, Phillips CD, Steinke JW. Chronic
hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated
respiratory disease. Ann Allergy Asthma Immunol. 2005;94:652–7.
36. Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER,
Borish L. Aspirin sensitivity and severity of asthma: evidence for
irreversible airway obstruction in patients with severe or difficult-
to-treat asthma. J Allergy Clin Immunol. 2005;116:970–5.
37. American Thoracic Society (ATS). Proceedings of the ATS workshop on
refractory asthma: current understanding, recommendations, and unan-
swered questions. Am J Respir Crit Care Med. 2000;162:2341–51.
Curr Respir Care Rep (2012) 1:259–269 269